Chemomab Therapeutics Ltd DRC (CMMB) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Chemomab Therapeutics Ltd DRC (CMMB) has a cash flow conversion efficiency ratio of -0.910x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-11.22 Million) by net assets ($12.33 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See CMMB defensive interval ratio to measure how many days the company can operate on defensive assets alone.
Chemomab Therapeutics Ltd DRC - Cash Flow Conversion Efficiency Trend (2015–2025)
This chart illustrates how Chemomab Therapeutics Ltd DRC's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Chemomab Therapeutics Ltd DRC Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Chemomab Therapeutics Ltd DRC ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Lien Hoe Corporation Bhd
KLSE:3573
|
0.027x |
|
Future Metals NL
AU:FME
|
-0.069x |
|
Rewardle Holdings Ltd
AU:RXH
|
-0.038x |
|
KDA Group Inc
V:KDA
|
-0.009x |
|
NPK Co.Ltd
KQ:048830
|
0.058x |
|
Mercury Industries Bhd
KLSE:8192
|
-0.020x |
|
Techcential International Ltd
TWO:6616
|
0.038x |
|
B.A.G Films and Media Limited
NSE:BAGFILMS
|
-0.017x |
Annual Cash Flow Conversion Efficiency for Chemomab Therapeutics Ltd DRC (2015–2025)
The table below shows the annual cash flow conversion efficiency of Chemomab Therapeutics Ltd DRC from 2015 to 2025. For the full company profile with market capitalisation and key ratios, see CMMB market cap overview.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $12.33 Million | $-11.22 Million | -0.910x | +20.35% |
| 2024-12-31 | $13.54 Million | $-15.46 Million | -1.142x | +17.58% |
| 2023-12-31 | $17.00 Million | $-23.55 Million | -1.386x | -147.35% |
| 2022-12-31 | $36.22 Million | $-20.29 Million | -0.560x | -178.05% |
| 2021-12-31 | $61.47 Million | $-12.38 Million | -0.201x | +83.00% |
| 2020-12-31 | $10.80 Million | $-12.80 Million | -1.185x | -7.01% |
| 2019-12-31 | $14.91 Million | $-16.51 Million | -1.107x | +23.41% |
| 2018-12-31 | $9.80 Million | $-14.18 Million | -1.446x | -110.26% |
| 2017-12-31 | $-609.00K | $-8.58 Million | 14.090x | +1342.12% |
| 2016-12-31 | $3.29 Million | $-3.74 Million | -1.134x | +67.03% |
| 2015-12-31 | $2.14 Million | $-7.38 Million | -3.441x | -- |
About Chemomab Therapeutics Ltd DRC
Chemomab Therapeutics Ltd., a clinical-stage biotechnology company, focuses on the discovery and development of therapeutics for the treatment of fibrotic and inflammatory diseases. Its lead product candidate is nebokitug, a humanized monoclonal antibody that attenuates the basic function of CCL24 as a regulator of major inflammatory and fibrotic pathways, which has completed phase 2 clinical tri… Read more